Wytwarzanie produktów leczniczych jest dla nas nie tylko kwestia wykonania pewnego procesu technologicznego, ale misją związaną z człowiekiem opartą na wysokim standardzie jakości, bezpieczeństwa i skuteczności leków.
Mamy aktywną i kluczową rolę w podnoszeniu standardów życia codziennego. Sprawiamy, że społeczeństwo jest lepiej poinformowane, zdrowsze, szczęśliwsze i bezpieczniejsze
Sofia, Bulgaria, August 6, 2025 – According to the requirements of art. 17 of the Regulation (EU) No 596/2014 of the European Parliament and of the Council, “Sopharma” AD (SFA: Bulgarian Stock Exchange, SPH: Warsaw Stock Exchange) notifies that on August 4, 2025 the Company sold 770 286 (seven hundred thousand two hundred eighty-six) repurchased own shares representing 0.14% of the share capital of the Company, at a total value of BGN 1 871 797.84 on the Bulgarian Stock Exchange, the average price per share was BGN 2.43.
Sofia, Bulgaria, August 5, 2025 – According to the requirements of art. 17 of the Regulation (EU) No 596/2014 of the European Parliament and of the Council, “Sopharma” AD (SFA: Bulgarian Stock Exchange, SPH: Warsaw Stock Exchange) corrects the text of the following notifications regarding sold repurchased shares due to a technical mistake as follows:
In notification of sale of treasury shares as of July 31, 2025:
The text:
“The total number of treasury shares after this transaction is 26 060 100 representing 4.83% of the share capital of the Company.”
Sofia, Bulgaria, August 4, 2025 – According to the requirements of art. 17 of the Regulation (EU) No 596/2014 of the European Parliament and of the Council, “Sopharma” AD (SFA: Bulgarian Stock Exchange, SPH: Warsaw Stock Exchange) notifies that on August 1, 2025 the Company sold 10 500 (ten thousand five hundred) repurchased own shares representing 0.002% of the share capital of the Company, at a total value of BGN 25 625.00 on the Bulgarian Stock Exchange, the average price per share was BGN 2.44.
Sofia, Bulgaria, August 1, 2025 – According to the requirements of art. 17 of the Regulation (EU) No 596/2014 of the European Parliament and of the Council, “Sopharma” AD (SFA: Bulgarian Stock Exchange, SPH: Warsaw Stock Exchange) notifies that on July 31, 2025 the Company sold 2 400 (two thousand four hundred) repurchased own shares representing 0.0004% of the share capital of the Company, at a total value of BGN 5 778.00 on the Bulgarian Stock Exchange, the average price per share was BGN 2.41.
Sofia, Bulgaria, July 31, 2025 – According to the requirements of art. 17 of the Regulation (EU) No 596/2014 of the European Parliament and of the Council, “Sopharma” AD (SFA: Bulgarian Stock Exchange, SPH: Warsaw Stock Exchange) notifies that on July 30, 2025 the Company sold 28 500 (twenty-eight thousand five hundred) repurchased own shares representing 0.01% of the share capital of the Company, at a total value of BGN 68 969.00 on the Bulgarian Stock Exchange, the average price per share was BGN 2.42.